drugset
drugset / Trial / NCT03115255

Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

NCT03115255 ↗

Completed 17 enrolled Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelHealth-services research

Summary

To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab

Timeline

Start
2017-05-01
Primary completion
2018-05-31
Completion
2018-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.25 mg Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications

perinatal disease